Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.

Dean JP, Sprenger CC, Wan J, Haugk K, Ellis WJ, Lin DW, Corman JM, Dalkin BL, Mostaghel E, Nelson PS, Cohen P, Montgomery B, Plymate SR.

J Clin Endocrinol Metab. 2013 May;98(5):E820-8. doi: 10.1210/jc.2012-3856. Epub 2013 Mar 26.

2.

SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.

Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr.

J Clin Oncol. 2015 May 10;33(14):1601-8. doi: 10.1200/JCO.2014.59.4127. Epub 2015 Apr 6.

3.

Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.

Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.

Urology. 2013 Mar;81(3):611-6. doi: 10.1016/j.urology.2012.12.025.

PMID:
23452809
4.

A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.

Amato R, Stepankiw M, Gonzales P.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1629-34. doi: 10.1007/s00280-013-2163-4. Epub 2013 Apr 21.

PMID:
23604530
5.

Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.

Mason M, Maldonado Pijoan X, Steidle C, Guerif S, Wiegel T, van der Meulen E, Bergqvist PB, Khoo V.

Clin Oncol (R Coll Radiol). 2013 Mar;25(3):190-6. doi: 10.1016/j.clon.2012.09.010. Epub 2012 Dec 17.

PMID:
23257248
6.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.

BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13.

7.

Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.

Hara N, Takizawa I, Isahaya E, Nishiyama T, Hoshii T, Ishizaki F, Takahashi K.

Urol Oncol. 2012 Sep;30(5):596-601. doi: 10.1016/j.urolonc.2010.11.001. Epub 2011 Apr 1.

PMID:
21458314
8.

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM.

J Clin Oncol. 2011 May 20;29(15):2040-5. doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.

9.

A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.

Sayyid RK, Evans A, Hersey K, Maloni R, Hurtado-Coll A, Kulkarni G, Finelli A, Zlotta AR, Hamilton R, Gleave M, Fleshner NE.

Clin Cancer Res. 2017 Apr 15;23(8):1974-1980. doi: 10.1158/1078-0432.CCR-16-1790. Epub 2016 Oct 18.

PMID:
27756786
10.

Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.

Montironi R, Diamanti L, Santinelli A, Galetti-Prayer T, Zattoni F, Selvaggi FP, Pagano F, Bono AV.

Pathol Res Pract. 1999;195(4):201-8.

PMID:
10337657
11.

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Mostaghel EA, Nelson PS, Lange P, Lin DW, Taplin ME, Balk S, Ellis W, Kantoff P, Marck B, Tamae D, Matsumoto AM, True LD, Vessella R, Penning T, Hunter Merrill R, Gulati R, Montgomery B.

J Clin Oncol. 2014 Jan 20;32(3):229-37. doi: 10.1200/JCO.2012.48.6431. Epub 2013 Dec 9.

12.

Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.

Jang JW, Hwang WT, Guzzo TJ, Wein AJ, Haas NB, Both S, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1493-9. doi: 10.1016/j.ijrobp.2011.10.047. Epub 2012 Mar 6.

PMID:
22401922
13.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

14.

Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.

Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H.

Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):753-60. doi: 10.1016/j.ijrobp.2013.07.023. Epub 2013 Sep 10.

PMID:
24035332
15.

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.

McNeel DG, Smith HA, Eickhoff JC, Lang JM, Staab MJ, Wilding G, Liu G.

Cancer Immunol Immunother. 2012 Jul;61(7):1137-47. doi: 10.1007/s00262-011-1193-1. Epub 2011 Dec 31.

16.

Sunitinib plus androgen deprivation and radiation therapy for patients with localized high-risk prostate cancer: results from a multi-institutional phase 1 study.

Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, DePetrillo TA, Mathew P.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):540-5. doi: 10.1016/j.ijrobp.2012.12.029. Epub 2013 Mar 28.

17.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database.

Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, Freedland SJ.

BJU Int. 2012 Aug;110(4):492-8. doi: 10.1111/j.1464-410X.2011.10754.x. Epub 2011 Nov 17.

18.

Decline of the red blood cell count in patients receiving androgen deprivation therapy for localized prostate cancer: impact of ADT on insulin-like growth factor-1 and erythropoiesis.

Hara N, Nishiyama T, Takizawa I, Saito T, Kitamura Y, Takahashi K.

Urology. 2010 Jun;75(6):1441-5. doi: 10.1016/j.urology.2009.11.021. Epub 2010 Jan 29.

PMID:
20110105
19.

The effect of concurrent androgen deprivation and 3D conformal radiotherapy on prostate volume and clinical organ doses during treatment for prostate cancer.

Onal C, Topkan E, Efe E, Yavuz M, Arslan G, Yavuz A.

Br J Radiol. 2009 Dec;82(984):1019-26. doi: 10.1259/bjr/65939531. Epub 2009 Jul 6.

20.

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.

Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE.

Urology. 1997 Mar;49(3A Suppl):46-55.

PMID:
9123736

Supplemental Content

Support Center